ImmunityBio's Plunge: FDA Warning and Lawsuit Trigger Alarm Bells for Investors

ImmunityBio, Inc. (IBRX) has seen its market capitalization decimated after receiving a warning from the FDA regarding unsubstantiated claims about its cancer treatment. The company’s stock plummeted following the warning, wiping out a $2 billion market capitalization. A class-action lawsuit has been filed by Hagens Berman, raising serious questions about the company’s assertions and highlighting the increasing scrutiny from regulatory bodies and the critical need for investor protection.

FDA Warning and Lawsuit Trigger: Amplified Uncertainty for the Company’s Future

ImmunityBio’s recent stock plunge goes beyond mere market volatility; it raises serious questions about the company’s business model and future prospects. According to GlobeNewswire on April 1, 2026, the FDA issued a formal warning regarding ImmunityBio’s claims about its cancer treatment, citing a lack of sufficient evidence to support them. This reflects the regulatory body’s serious concerns about the company’s core product and serves as an immediate warning sign for investors.

Concerns from Key Regulatory Bodies

The FDA’s warning emphasizes that ImmunityBio has not presented sufficient data to demonstrate the efficacy of its treatment as a cancer therapy. This suggests that the company’s assertions may be exaggerated or lack scientific grounding, creating significant uncertainty regarding potential future regulatory approvals. The increasing scrutiny from regulatory bodies is raising investors’ awareness across the pharmaceutical industry.

Hagens Berman’s Lawsuit Filed

Hagens Berman Law Firm has filed a class-action lawsuit against ImmunityBio on behalf of shareholders. The lawsuit alleges that the company engaged in misleading promotional practices and deceived investors regarding its financial status and business model, demanding a thorough investigation into the matter. The outcome of the lawsuit could significantly impact the company’s future and requires investors to closely monitor its progress.

Market Reaction and Decline in Market Capitalization

The market’s reaction to the FDA warning and the lawsuit filing was immediate and forceful. The stock plummeted, erasing a $2 billion market capitalization, clearly demonstrating a loss of investor confidence. This situation highlights the risks associated with similar cases and underscores the need for careful consideration when making investment decisions.